Scholarlink

Rationale <p>Conventional pharmacotherapy for depression faces numerous challenges, including side effects. Moreover, less than 50–70% of patients fully respond to treatment, and 20–30% experience recurrence. This has led to a growing interest in alternative treatments, particularly phytotherapy. Among various plant-based compounds, asiatic acid has gained attention due to its multidirectional therapeutic properties.</p> Objective <p>The aim of this study was to evaluate whether asiatic acid could enhance the antidepressant effects of conventional drugs (imipramine, reboxetine, and escitalopram).</p> Methods <p>The antidepressant-like effect was tested by the forced swim test and in the tail suspension test in male Albino Swiss mice. Additionally, pharmacokinetic studies and biochemical analyses were carried out.</p> Results <p>According to obtained results, asiatic acid at a sub-active dose (5&#xa0;mg/kg) significantly potentiates the antidepressant activity of imipramine (15&#xa0;mg/kg), reboxetine (2.5&#xa0;mg/kg), and escitalopram (2&#xa0;mg/kg). It was demonstrated that asiatic acid (5&#xa0;mg/kg) did not increase serum or brain levels of the tested antidepressants. However, when given concurrently with escitalopram (2&#xa0;mg/kg) it elevated concentrations of catalase and glutathione peroxidase as well as decreased levels of TBARS in mice brains. Co-administration of asiatic acid with imipramine (15&#xa0;mg/kg) and reboxetine (2.5&#xa0;mg/kg) reduced concentrations of TBARS in the tested tissue.</p> Conclusions <p>Our findings give a new light on the potential use of asiatic acid in the management of depression. The terpenoid has antidepressant properties, potentially making it a valuable addition/adjunct to conventional treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Asiatic acid potentiates the activity of common antidepressant drugs in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月24日

查看全文
  • Ewa Poleszak,
  • Sylwia Wośko,
  • Bernadeta Szewczyk,
  • Elżbieta Wyska,
  • Aleksandra Szopa,
  • Andrzej Wróbel,
  • Jarosław Szponar,
  • Piotr Wlaź,
  • Dorota Ołtarzewska,
  • Weronika Słotwińska,
  • Agnieszka Czylkowska,
  • Anna Serefko

摘要

Rationale

Conventional pharmacotherapy for depression faces numerous challenges, including side effects. Moreover, less than 50–70% of patients fully respond to treatment, and 20–30% experience recurrence. This has led to a growing interest in alternative treatments, particularly phytotherapy. Among various plant-based compounds, asiatic acid has gained attention due to its multidirectional therapeutic properties.

Objective

The aim of this study was to evaluate whether asiatic acid could enhance the antidepressant effects of conventional drugs (imipramine, reboxetine, and escitalopram).

Methods

The antidepressant-like effect was tested by the forced swim test and in the tail suspension test in male Albino Swiss mice. Additionally, pharmacokinetic studies and biochemical analyses were carried out.

Results

According to obtained results, asiatic acid at a sub-active dose (5 mg/kg) significantly potentiates the antidepressant activity of imipramine (15 mg/kg), reboxetine (2.5 mg/kg), and escitalopram (2 mg/kg). It was demonstrated that asiatic acid (5 mg/kg) did not increase serum or brain levels of the tested antidepressants. However, when given concurrently with escitalopram (2 mg/kg) it elevated concentrations of catalase and glutathione peroxidase as well as decreased levels of TBARS in mice brains. Co-administration of asiatic acid with imipramine (15 mg/kg) and reboxetine (2.5 mg/kg) reduced concentrations of TBARS in the tested tissue.

Conclusions

Our findings give a new light on the potential use of asiatic acid in the management of depression. The terpenoid has antidepressant properties, potentially making it a valuable addition/adjunct to conventional treatment.